Disease Markers

Biomarkers in Multiple Sclerosis


Status
Published

Guest Editors

Biomarkers in Multiple Sclerosis

Articles

  • Special Issue
  • - Volume 22
  • - Article ID 728296
  • - Regular Article

Biomarkers that Discriminate Multiple Myeloma Patients with or without Skeletal Involvement Detected Using SELDI-TOF Mass Spectrometry and Statistical and Machine Learning Tools

Sudeepa Bhattacharyya | Joshua Epstein | Larry J. Suva
  • Special Issue
  • - Volume 22
  • - Article ID 670439

Comprehensive Phenotyping in Multiple Sclerosis: Discovery Based Proteomics and the Current Understanding of Putative Biomarkers

Kevin C. O’Connor | Sushmita Mimi Roy | ... | Aaron B. Kantor
  • Special Issue
  • - Volume 22
  • - Article ID 709869

Biomarkers Indicative of Blood-Brain Barrier Disruption in Multiple Sclerosis

Emmanuelle Waubant
  • Special Issue
  • - Volume 22
  • - Article ID 740493
  • - Regular Article

DHPLC Screening of ATM Gene in Italian Patients Affected by Ataxia-Telangiectasia: Fourteen Novel ATM Mutations

Monia Magliozzi | Maria Piane | ... | Luciana Chessa
  • Special Issue
  • - Volume 22
  • - Article ID 602103

Biomarkers in Multiple Sclerosis: Role of Antibodies

Thomas Berger | Markus Reindl
  • Special Issue
  • - Volume 22
  • - Article ID 786720
  • - Regular Article

Expression of Telomerase Reverse Transcriptase in Psoriatic Lesional Skin

Moushira A. Mahmoud | Roshdy W. Mohamed | ... | Samir M. Abdel-moneim
  • Special Issue
  • - Volume 22
  • - Article ID 586306

NMO-IgG: A Specific Biomarker for Neuromyelitis Optica

Brian G. Weinshenker | Dean M. Wingerchuk | ... | Vanda A. Lennon
  • Special Issue
  • - Volume 22
  • - Article ID 508354
  • - Introduction

Biomarkers in Multiple Sclerosis

Roland Martin | Bibiana Bielekova | ... | Ursula Utz
  • Special Issue
  • - Volume 22
  • - Article ID 509476

Multiple Sclerosis Cerebrospinal Fluid Biomarkers

Gavin Giovannoni
  • Special Issue
  • - Volume 22
  • - Article ID 694283

Chemokine Receptors as Biomarkers in Multiple Sclerosis

Robert J. Fox | Pia Kivisäkk | ... | Richard M. Ransohoff
Disease Markers
 Journal metrics
Acceptance rate34%
Submission to final decision88 days
Acceptance to publication43 days
CiteScore3.500
Impact Factor2.738
 Submit

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.